Seach Medical Group Ltd

Seach Medical Group Ltd maintains a conservative capital structure with a debt-to-equity ratio of 0.19, indicating limited leverage. The company's liquidity position is characterized by a current ratio of 3.49, suggesting strong short-term liquidity. However, the company's free cash flow is negative at -679,000 ILS, and capital expenditures are -1,101,000 ILS, indicating ongoing investment in operations. Profitability metrics show a return on equity of 1.71% and a return on assets of 1.1%, both below the industry median for Drug Retailers. The company's operating income of 4,220,000 ILS and net income of 1,524,000 ILS reflect modest profitability, with gross profit of 48,548,000 ILS representing 30.9% of revenue. The company's revenue is concentrated in a single business segment focused on medical cannabis, with no disclosed geographic diversification. This concentration increases exposure to regulatory and market risks in the medical cannabis industry. Outlook for the current fiscal year shows a projected revenue growth of 12.5%, driven by expansion in cultivation capacity and new product launches. For the next fiscal year, revenue is expected to grow by 8.3%, reflecting continued market penetration in existing markets. Risk factors include a medium liquidity risk due to negative net cash after subtracting total debt. The company has a low dilution potential, with no recent share issuance or shelf registration activity. Adjustments in the valuation model reflect conservative assumptions about future cash flows and market conditions. Recent events include the filing of the 10-K for the fiscal year ending 2026-04-15, which disclosed ongoing regulatory compliance efforts and expansion plans. No material earnings call transcripts were available for the last quarter.